Vaxart Conference Call Summary Company Overview - **Company**: Vaxart - **Industry**: Biotechnology, specifically focusing on oral vaccine development Key Developments - **Acquisition**: Sanofi acquired Dynavax, Vaxart's partner, in February 2026, which is expected to enhance collaboration on the oral COVID-19 vaccine program [4][6] - **Cash Runway**: Vaxart has a cash runway extending into the second quarter of 2027, allowing for continued operations without immediate need for capital raising [4][20] - **Clinical Trials**: The company is prioritizing the execution of its Phase 2B COVID-19 trial, with expected top-line data from a 400-participant cohort in early Q2 2026 [5][28] Clinical Programs - **COVID-19 Vaccine**: - Collaboration with BARDA for funding the Phase 2B trial [8] - A $50 million milestone payment is contingent upon advancing to Phase 3 after Phase 2B results [9][28] - **Norovirus Program**: - The start of the Phase 2B trial is contingent on securing a strategic partnership or non-dilutive funding [11][12] - Positive results from a study on lactating mothers suggest potential for mucosal immunity transfer to infants [12][41] - **Avian Influenza**: - Completed primary analysis showing 100% protection in a ferret model, with plans to publish results in a peer-reviewed journal [33] Financial Management - **Cost Management**: - Recent lease termination expected to save over $1 million annually [31] - Headcount reduced from 105 in 2024 to 65 in 2025, allowing for consolidation of operations [74] - **Funding Strategy**: - Preference for non-dilutive funding through partnerships, but open to other financing options if necessary [21][50] Market Position and Strategy - **Competitive Advantage**: - Vaxart's oral vaccine platform addresses vaccine fatigue and needle hesitancy, positioning it uniquely in the market [25] - Global demand for effective immunization remains strong, with significant funding from international stakeholders [26] - **Partnership Discussions**: - Ongoing discussions with potential partners for various programs, including avian flu and norovirus [48][46] - Interest in the entire oral vaccine platform beyond traditional licensing [46] Regulatory and Compliance - **FDA Interactions**: - Vaxart maintains operational responsibility for the COVID-19 program until the completion of the Phase 2B trial [8] - The company is working closely with BARDA to finalize data release timelines, which have been delayed from Q1 to early Q2 2026 [17][81] Future Outlook - **Next Steps**: - If COVID-19 trial data is positive, Vaxart will submit a data package to the FDA for potential advancement to Phase 3 [28] - The company is exploring additional funding opportunities and partnerships to support ongoing and future clinical trials [14][16] Additional Insights - **Market Sentiment**: - The domestic vaccine environment is characterized by increased scrutiny, but Vaxart's unique delivery method may help re-engage the market [25] - **Operational Adjustments**: - Consolidation of facilities and reduction in manufacturing footprint to align with strategic goals and cost management [90] This summary encapsulates the key points discussed during the Vaxart conference call, highlighting the company's strategic direction, clinical programs, financial management, and market positioning.